South Korean FDA
Bridge Biotherapeutics' IND for EGFR Inhibitor Accepted by South Korean Regulators
The company will now initiate the dose escalation portion of a Phase I/II study and will enroll 90 NSCLC patients in the country.
Bridge Biotherapeutics Files IND for Lung Cancer Drug Targeting EGFR Resistance Mutation
The drug is designed to tackle C797S resistance mutations that arise in NSCLC patients after treatment with third-generation tyrosine kinase inhibitors.